Sanofi (ETR: SNW)
Germany
· Delayed Price · Currency is EUR | Market Cap | 123.34B |
| Revenue (ttm) | 48.45B |
| Net Income (ttm) | 4.51B |
| Shares Out | n/a |
| EPS (ttm) | 3.59 |
| PE Ratio | 27.37 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | May 13, 2024 |
| Volume | 1,322 |
| Average Volume | 7,507 |
| Open | 98.44 |
| Previous Close | 98.17 |
| Day's Range | 98.20 - 98.63 |
| 52-Week Range | 85.00 - 106.08 |
| Beta | 0.45 |
| RSI | 65.76 |
| Earnings Date | Jan 30, 2025 |
About Sanofi
Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products. In addition, it offers poliomyelitis, pertussis, and hib pediatric ... [Read more]
Financial Performance
In 2023, Sanofi's revenue was 46.03 billion, an increase of 1.42% compared to the previous year's 45.39 billion. Earnings were 5.40 billion, a decrease of -35.49%.
Financial StatementsNews
Top 4 Immunology Stocks Poised For Growth In 2025
This article will reveal an in-depth analysis of drugs being developed to combat immunological disorders. Big Pharma is keenly interested in the global immunology drugs market, which is anticipated to...
Sanofi (SYN) CEO Paul Hudson Hosts 43rd Annual J.P. Morgan Healthcare (Transcript)
Top 5 Cancer Pharma Stocks With Strong Risk/Reward In 2025
This article will provide an in-depth analysis of drugs being developed to combat cancer. Big Pharma is keenly interested in the global cancer therapeutics market, which is expected to exceed $400 bil...
Scribe Therapeutics Achieves Milestone for In Vivo Program in Collaboration with Sanofi
ALAMEDA, Calif.--(BUSINESS WIRE)-- #CRISPR--Scribe Therapeutics achieves milestone for in vivo program in collaboration with Sanofi.
Press Release: Sarclisa obtains first approval in China for the treatment of adult patients with relapsed or refractory multiple myeloma
Sarclisa obtains first approval in China for the treatment of adult patients with relapsed or refractory multiple myeloma
Sanofi: Underappreciated Powerhouse Primed For Long-Term Growth (Rating Upgrade)
Sanofi’s Dupixent and new drugs drive growth, despite near-term pressures. See why SFY stock’s product pipeline makes it a potential long-term winner.
Price Over Earnings Overview: Sanofi
Looking into the current session, Sanofi Inc. (NASDAQ: SNY) shares are trading at $49.35, after a 0.24% increase. Moreover, over the past month, the stock went up by 5.45% , but in the past year, fel...
Why Novavax Stock Is Volatile This Week
Novavax Inc (NASDAQ: NVAX) shares dipped 11.2% to $9.60 during Wednesday’s session, pulling back following recent strength. Shares of vaccine makers are volatile this week after the first bird flu de...
Sanofi reports positive results for subcutaneous Sarclisa
Sanofi's Blood Cancer Drug's New Subcutaneous Formulation Hits Primary Goal In Late-Stage In Multiple Myeloma
On Thursday, Sanofi SA (NASDAQ: SNY) released results from the IRAKLIA phase 3 study evaluating the non-inferiority of Sarclisa (isatuximab) subcutaneous formulation via an on-body delivery system (O...
Press Release: New Sarclisa subcutaneous formulation met co-primary endpoints in the IRAKLIA phase 3 study in multiple myeloma
New Sarclisa subcutaneous formulation met co-primary endpoints in the IRAKLIA phase 3 study in multiple myeloma Sarclisa SC formulation added to Pd for the treatment of R/R MM met the co-primary endpo...
Vir jumps after Phase 1 data for Sanofi-partnered cancer drug technology
Vir Biotechnology (CIR) stock surged 42% after positive Phase 1 data for two antitumor agents developed using Sanofi's (SNY) PRO-XTEN technology. Read more here.
Alloy Therapeutics Announces a Target Specific Collaboration and License Agreement for use of AntiClastic™ Antisense Platform with Sanofi
BOSTON--(BUSINESS WIRE)--Alloy Therapeutics Inc. (“Alloy”), a biotechnology ecosystem company dedicated to democratizing access to cutting edge drug discovery technologies, announced today a target sp...
Gaming stocks likely to outperform semiconductor stocks in 2025
As 2025 draws near, the financial spotlight is moving from semiconductor companies to gaming stocks. Video game companies have been a bright spot for investors amid global unpredictability due to a sp...
Drugmakers to raise US prices on over 250 medicines starting Jan. 1
Drugmakers plan to raise U.S. prices on at least 250 branded medications including Pfizer COVID-19 treatment Paxlovid, Bristol Myers Squibb's cancer cell therapies and vaccines from France's Sanofi at...
Drugmakers to raise US prices on over 250 medicines starting Jan. 1
Drugmakers plan to raise U.S. prices on at least 250 branded medications including Pfizer COVID-19 treatment Paxlovid, Bristol Myers Squibb's cancer cell therapies and vaccines from France's Sanofi at...
How Is The Market Feeling About Sanofi?
Sanofi's (NYSE: SNY) short percent of float has fallen 15.0% since its last report. The company recently reported that it has 3.74 million shares sold short , which is 0.17% of all regular shares tha...
A Look Into Sanofi Inc's Price Over Earnings
In the current session, Sanofi Inc. (NASDAQ: SNY) is trading at $48.30, after a 0.18% decrease. Over the past month, the stock decreased by 0.88% , and in the past year, by 2.21% . With performance l...
Press Release: Sanofi initiates phase 3 program for PCV21 and expands collaboration with SK bioscience for next-generation pneumococcal conjugate vaccines
Sanofi initiates phase 3 program for PCV21 and expands collaboration with SK bioscience for next-generation pneumococcal conjugate vaccines
Teva Pharmaceutical, Li Auto, And Darden Restaurants Are Among Top Large Cap Gainers Last Week (December 16-20): Are The Others In Your Portfolio?
These ten large-cap stocks were the best performers in the last week. Are they in your portfolio? Teva Pharmaceutical Industries Limited (NYSE: TEVA) stock escalated 33.88% after the company and Sano...
Sanofi to buy China rights to Cytokinetics lead asset
Cytokinetics (CYTK) stock is in focus as Sanofi (SNY) agrees to buy exclusive rights to its lead drug aficamten in Greater China. Read more here.
Cytokinetics Inc (CYTK) Announces Sanofi's Acquisition of Aficamten Rights in Greater China
Cytokinetics Inc (CYTK) Announces Sanofi's Acquisition of Aficamten Rights in Greater China
Presse release: Jean-Paul Kress to join Sanofi's Board of Directors
Jean-Paul Kress to join Sanofi's Board of Directors Paris, December 19, 2024. Sanofi's Board of Directors is pleased to welcome Jean-Paul Kress as an independent director as of January 1, 2025, replac...
Teva Pharmaceutical Releases Impressive Phase 2 Candidate Data For Gastro-Related Diseases
Teva and Sanofi report positive Phase 2b data for duvakitug, showing significant remission in UC and CD patients, boosting analyst confidence and price targets. ... Full story available on Benzinga.co...
Sanofi and Teva Achieve Milestone in Ulcerative Colitis Treatment Study
Sanofi and Teva Achieve Milestone in Ulcerative Colitis Treatment Study